CIK 2104501
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 100.00% | 6 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | ORKA | Oruka Therapeutics, Inc. | Health Care | 27.31% |
| 2 | SYRE | Spyre Therapeutics, Inc. | Health Care | 26.13% |
| 3 | DMRA | Damora Therapeutics, Inc. | Health Care | 18.84% |
| 4 | APGE | Apogee Therapeutics, Inc. | Health Care | 17.47% |
| 5 | JBIO | Jade Biosciences, Inc. | Health Care | 7.88% |
| 6 | CBIO | CRESCENT BIOPHARMA, INC. | Health Care | 2.36% |
6/6 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 100.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/6 names) · unclassified 100.0%: ORKA, SYRE, DMRA, APGE, JBIO, CBIO. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | ORKAORUKA THERAPEUTICS INC | 1,565,661 | $77M | 27.3% | HOLD |
| 2 | SYRESPYRE THERAPEUTICS INC | 1,456,231 | $73M | 26.1% | HOLD |
| 3 | DMRADAMORA THERAPEUTICS INC | 2,045,473 | $53M | 18.8% | ADD 1598% |
| 4 | APGEAPOGEE THERAPEUTICS INC | 583,591 | $49M | 17.5% | HOLD |
| 5 | JBIOJADE BIOSCIENCES INC | 1,577,750 | $22M | 7.9% | HOLD |
| 6 | CBIOCrescent Biopharma Inc | 361,250 | $7M | 2.4% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| ORKAORUKA THERAPEUTICS INC | — | — | — | — | 1.6M | 1.6M | $77M |
| SYRESPYRE THERAPEUTICS INC | — | — | — | — | 1.5M | 1.5M | $73M |
| DMRADAMORA THERAPEUTICS INC | — | — | — | — | 120K | 2.0M | $53M |
| APGEAPOGEE THERAPEUTICS INC | — | — | — | — | 584K | 584K | $49M |
| JBIOJADE BIOSCIENCES INC | — | — | — | — | 1.6M | 1.6M | $22M |
| CBIOCrescent Biopharma Inc | — | — | — | — | 361K | 361K | $7M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
